Abbott Laboratories has announced that it has received clearance from the U.S. Food and Drug Administration (FDA), along with CE Mark approval, for its next-generation Ultreon™ 3.0 Software. This milestone marks a significant advancement, as the platform integrates coronary imaging with AI-driven insights in a single system. As a result, it aims to enhance patient outcomes while reducing procedural risks.
AI-Powered Imaging for Precision Cardiac Care
At its core, Ultreon 3.0 is an artificial intelligence-powered imaging platform that uses Optical Coherence Tomography (OCT). It provides doctors with real-time guidance during minimally invasive procedures known as percutaneous coronary intervention (PCI), which are used to open blocked heart arteries.
As per Abbott’s press release, the system enables physicians to visualize the detailed structure of arterial blockages. By incorporating AI, it can assess the type of plaque present and guide clinicians in selecting the optimal stent size and placement. Consequently, this improves blood flow and supports more precise, efficient procedures through a fully integrated workflow.
Experts Highlight Transformational Impact
Emphasizing the innovation, Evan Shlofmitz, Director of Interventional Cardiology at St. Francis Hospital in New York, stated that Ultreon 3.0 represents a pivotal leap forward in patient care. He noted that by combining imaging with AI, the platform delivers enhanced clarity, speed, and clinical insight, thereby enabling more confident decision-making and improved outcomes.
Similarly, David M. Leistner from Charité Campus Benjamin-Franklin in Berlin highlighted the platform’s ability to quickly capture essential images. He stressed that in time-sensitive cardiac procedures, faster and more informed decisions can significantly impact patient outcomes, and Ultreon 3.0 supports this need effectively.
Advanced Features for Faster and Safer Procedures
In addition, the software introduces a one-second OCT pullback, a high-speed infrared imaging technique that captures detailed cross-sectional views of coronary arteries. Compared to intravascular ultrasound, it provides higher resolution imaging while using low or no contrast. This feature is particularly beneficial for patients with kidney disease, who account for nearly 25% of individuals with coronary artery disease.
Furthermore, Ultreon 3.0 offers several advanced capabilities:
- It provides a clear understanding of the size, shape, and location of arterial blockages, enabling optimal stent placement.
- It supports post-procedure assessments to confirm improved blood flow.
- It streamlines workflow through simplified setup and AI-automated insights.
- It enables efficient imaging and planning for patients with complex coronary conditions.
Driving Innovation in Complex PCI Procedures
Importantly, the platform plays a crucial role in advancing complex PCI procedures, which treat severe coronary artery disease involving challenging plaques. Many patients undergoing PCI require multiple stents to restore blood flow. Each year, more than 600,000 procedures are performed in the United States and over 885,000 in Europe.
Reinforcing Leadership in AI-Driven Healthcare
According to Ethan Korngold, Chief Medical Officer of Abbott’s vascular business, Ultreon 3.0 transforms OCT imaging into a powerful tool for precision-guided intervention before and after procedures. He added that innovations like this reinforce Abbott’s leadership in AI-powered imaging and its commitment to delivering smarter, more personalized coronary care.
A Step Forward in Clinical Precision
Ultimately, building on the success of its predecessor, Ultreon 2.0, the new platform introduces enhanced AI capabilities to meet real-world clinical demands. By combining speed, simplicity, and precision, Ultreon 3.0 supports consistent care delivery and sets a new benchmark in the treatment of complex coronary artery disease.